DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 10, 2014, Pages 1103-1107

  Sin Chan, Patrick ^a,b   Huang, Annie ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain tumor; C19MC; CNS primitive neuroectodermal tumors; DNA methyltransferases; Therapeutics

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; METHYL CPG BINDING PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE;

BRAIN CANCER; CANCER MORTALITY; CHILDHOOD CANCER; CHROMATIN CONDENSATION; CPG ISLAND; DEREGULATION; DNA METHYLATION; GENE SILENCING; GLIOBLASTOMA; HISTONE METHYLATION; NEUROECTODERM TUMOR; PHENOTYPE; PROMOTER REGION; REVIEW; RNA SEQUENCE; TUMOR SUPPRESSOR GENE; BRAIN NEOPLASMS; CHILD; DRUG DESIGN; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG DESIGN; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 84907048057     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.938052     Document Type: Review

References (18)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109
2. Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of children's oncology group trial A9961. Neuro Oncol 2013;15(1):97-103
3. Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009;16(6):533-46
4. Korshunov A, Ryzhova M, Jones DT, et al. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 2012;124(6):875-81
5. Spence T, Sin-Chan P, Picard D, et al. CNS-PNETS with C19MC amplification and/or lin28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 2014;128(2):291-303
6. Korshunov A, Sturm D, Ryzhova M, et al. Embryonal tumor with abundant neuropil and true rosettes (etantr), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 2014;128(2):279-89
7. Zhu H, Shyh-Chang N, Segre AV, et al. The lin28/let-7 axis regulates glucose metabolism. Cell 2011;147(1):81-94
8. Spence T, Perotti C, Sin-Chan P, et al. A novel c19mc amplified cell line links lin28/let-7 to mtor signaling in embryonal tumor with multilayered rosettes. Neuro Oncol 2014;16(1):62-71
9. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20(24):3139-55
10. Ioshikhes IP, Zhang MQ. Large-scale human promoter mapping using CpG islands. Nat Genet 2000;26(1):61-3
11. Suganuma T, Workman JL. Crosstalk among histone modifications. Cell 2008;135(4):604-7
12. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009;41(4):465-72
13. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482(7384):226-31
14. Kleinman CL, Gerges N, Papillon-Cavanagh S, et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet 2014;46(1):39-44
15. Huang J, Chen K, Huang J, et al. Regulation of the leucocyte chemoattractant receptor fpr in glioblastoma cells by cell differentiation. Carcinogenesis 2009;30(2):348-55
16. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2¢-deoxycytidine in rabbits and dogs. Cancer Res 1983;43(2):592-7
17. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase yy trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
18. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase y study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008;14(19):6296-301